• Lancet · Oct 2013

    The Global Drug Facility and its role in the market for tuberculosis drugs.

    • Nimalan Arinaminpathy, Thierry Cordier-Lassalle, Anant Vijay, and Christopher Dye.
    • Department of Ecology and Evolutionary Biology, Princeton University, NJ, USA. Electronic address: nimpathy@princeton.edu.
    • Lancet. 2013 Oct 19;382(9901):1373-9.

    AbstractUniversal access to high-quality treatment is central to the Global Plan to Stop TB. The Global Drug Facility (GDF) was launched in 2001 to help to achieve this goal, through services including the supply of affordable, quality-assured drugs to countries in need. We assess the scale of GDF drug supplies worldwide and find that the GDF commands a substantial proportion of the market for drugs for first-line and second-line treatment regimens, having supplied, for example, first-line drugs for roughly 35% of cases reported worldwide in 2011. Significant potential remains for GDF expansion, especially in the provision of second-line drugs, which would be aided by future increases in case detection.Copyright © 2013 Elsevier Ltd. All rights reserved.

      Pubmed     Full text   Copy Citation  

      Add institutional full text...

    Notes

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.